![Rachel Reiff](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Rachel Reiff
Nessuna posizione attualmente
Profilo
Rachel Reiff worked as the Head of Corporate Communications at Aratana Therapeutics, Inc.
Precedenti posizioni note di Rachel Reiff
Società | Posizione | Fine |
---|---|---|
ARATANA THERAPEUTICS INC | Public Communications Contact | 01/10/2019 |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 1 |
---|---|
Aratana Therapeutics, Inc.
![]() Aratana Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aratana Therapeutics, Inc. engages in the development and commercialization of pet therapeutics. Its portfolio includes NOCITA, ENTYCE, and GALLIPRANT. NOCITA (bupivacaine liposome injectable suspension) acts as a local post-operative analgesia for cranial cruciate ligament surgery in dogs, and as a peripheral nerve block to provide regional post-operative analgesia following onychectomy in cats. ENTYCE(capromorelin oral solution) is intended for appetite stimulation in dogs. GALLIPRANT (grapiprant tablets) is for the control of pain and inflammation associated with osteoarthritis in dogs. The company was founded by Linda Rhodes and Steven St. Peter on December 1, 2010 and is headquartered in Leawood, KS. | Health Technology |
- Borsa valori
- Insiders
- Rachel Reiff